Clinical trial
Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
NCT00413010 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00413010 |
|---|---|
| Title | Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD). |
| Official title | An 8-Week, Double-Blind, Placebo-Controlled, Phase 3 Trial of Pregabalin (150-600 mg/Day) in the Adjunctive Treatment of Patients With Generalized Anxiety Disorder (GAD) Who Have Not Optimally Responded to Existing Therapies(GAD) |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Generalized Anxiety Disorder |
| Intervention type | Drug |
| Interventions | pregabalin, placebo |
| Enrollment | 356 |
| Start date | Dec 1, 2006 |
| Primary completion | Feb 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Dec 19, 2006 |
| Last update posted | Feb 10, 2021 |
| Countries | Czechia, Estonia, Finland, Hungary, Russia, Serbia, Ukraine, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: